JP2009536526A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009536526A5 JP2009536526A5 JP2009510083A JP2009510083A JP2009536526A5 JP 2009536526 A5 JP2009536526 A5 JP 2009536526A5 JP 2009510083 A JP2009510083 A JP 2009510083A JP 2009510083 A JP2009510083 A JP 2009510083A JP 2009536526 A5 JP2009536526 A5 JP 2009536526A5
- Authority
- JP
- Japan
- Prior art keywords
- apoptosis
- zebrafish
- agent
- zpa
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000252212 Danio rerio Species 0.000 claims description 87
- 230000006907 apoptotic process Effects 0.000 claims description 81
- 238000000034 method Methods 0.000 claims description 80
- 229920001184 polypeptide Polymers 0.000 claims description 55
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 55
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 55
- 239000003795 chemical substances by application Substances 0.000 claims description 53
- 108090000623 proteins and genes Proteins 0.000 claims description 40
- 239000000203 mixture Substances 0.000 claims description 38
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 37
- 208000035475 disorder Diseases 0.000 claims description 37
- 230000009261 transgenic effect Effects 0.000 claims description 34
- 230000000694 effects Effects 0.000 claims description 24
- 102000004169 proteins and genes Human genes 0.000 claims description 20
- 108091033319 polynucleotide Proteins 0.000 claims description 18
- 239000002157 polynucleotide Substances 0.000 claims description 18
- 102000040430 polynucleotide Human genes 0.000 claims description 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 13
- 230000034727 intrinsic apoptotic signaling pathway Effects 0.000 claims description 12
- 239000002773 nucleotide Substances 0.000 claims description 10
- 125000003729 nucleotide group Chemical group 0.000 claims description 10
- 239000005557 antagonist Substances 0.000 claims description 9
- 238000000338 in vitro Methods 0.000 claims description 9
- 108091023037 Aptamer Proteins 0.000 claims description 8
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 8
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 8
- 230000000861 pro-apoptotic effect Effects 0.000 claims description 8
- 150000003384 small molecules Chemical class 0.000 claims description 8
- 230000004936 stimulating effect Effects 0.000 claims description 8
- 239000000427 antigen Substances 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 230000034725 extrinsic apoptotic signaling pathway Effects 0.000 claims description 6
- 230000000977 initiatory effect Effects 0.000 claims description 6
- 239000000556 agonist Substances 0.000 claims description 5
- 230000005775 apoptotic pathway Effects 0.000 claims description 5
- 230000002452 interceptive effect Effects 0.000 claims description 5
- 230000037361 pathway Effects 0.000 claims description 5
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 102000011727 Caspases Human genes 0.000 claims description 4
- 108010076667 Caspases Proteins 0.000 claims description 4
- 208000012902 Nervous system disease Diseases 0.000 claims description 4
- 230000004913 activation Effects 0.000 claims description 4
- 230000001640 apoptogenic effect Effects 0.000 claims description 4
- 230000003833 cell viability Effects 0.000 claims description 4
- 208000014951 hematologic disease Diseases 0.000 claims description 4
- 230000001418 larval effect Effects 0.000 claims description 4
- 230000002062 proliferating effect Effects 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- 230000009462 endogenous apoptosis Effects 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 102000054767 gene variant Human genes 0.000 claims description 2
- 238000010874 in vitro model Methods 0.000 claims description 2
- 108700020237 zebrafish bcl2a Proteins 0.000 claims description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- -1 antibodies Proteins 0.000 claims 1
- 241000124008 Mammalia Species 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79770306P | 2006-05-04 | 2006-05-04 | |
| PCT/US2007/068180 WO2007131133A2 (en) | 2006-05-04 | 2007-05-03 | Methods and compositions relating to zpa polypeptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009536526A JP2009536526A (ja) | 2009-10-15 |
| JP2009536526A5 true JP2009536526A5 (enExample) | 2011-06-16 |
Family
ID=38668571
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009510083A Pending JP2009536526A (ja) | 2006-05-04 | 2007-05-03 | Ｚｐａポリペプチドに関連する方法および組成物 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20100150928A1 (enExample) |
| EP (1) | EP2016097A2 (enExample) |
| JP (1) | JP2009536526A (enExample) |
| CN (1) | CN101479295A (enExample) |
| AU (1) | AU2007247969A1 (enExample) |
| BR (1) | BRPI0710407A2 (enExample) |
| CA (1) | CA2651199A1 (enExample) |
| IL (1) | IL194786A0 (enExample) |
| MX (1) | MX2008013934A (enExample) |
| NZ (1) | NZ572178A (enExample) |
| WO (1) | WO2007131133A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100008978A1 (en) * | 2008-05-09 | 2010-01-14 | The Regents Of The University Of California | Nanoparticles effective for internalization into cells |
| US20100009390A1 (en) * | 2008-05-09 | 2010-01-14 | The Regents Of The University Of California | Mutant antibodies with high affinity for egfr |
| US8846081B2 (en) | 2010-08-13 | 2014-09-30 | Rhode Island Board Of Governors For Higher Education | Liposome compositions and methods of use thereof |
| MX380902B (es) * | 2013-11-15 | 2025-03-12 | Genentech Inc | Métodos para la inactivación viral usando detergentes ecológico. |
| CR20200334A (es) | 2018-01-05 | 2021-03-09 | Cybrexa 1 Inc | Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas |
| MX2022000450A (es) | 2019-07-10 | 2022-04-25 | Cybrexa 3 Inc | Conjugados peptídicos de agentes dirigidos a microtúbulos como terapéuticos. |
| PH12022550039A1 (en) | 2019-07-10 | 2023-06-26 | Cybrexa 3 Inc | Peptide conjugates of cytotoxins as therapeutics |
| CN113470755B (zh) * | 2021-09-03 | 2021-11-19 | 深圳市第二人民医院(深圳市转化医学研究院) | 骨关节炎中调控软骨细胞凋亡信号通路的建模方法和应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| GB8724885D0 (en) | 1987-10-23 | 1987-11-25 | Binns M M | Fowlpox virus promotors |
| US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
| US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
| DE69029036T2 (de) | 1989-06-29 | 1997-05-22 | Medarex Inc | Bispezifische reagenzien für die aids-therapie |
| US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| DE69222303T2 (de) | 1991-04-30 | 1998-01-22 | Eukarion Inc | Kationisierte antikörper gegen intrazelluläre eiweisse |
| JPH06507398A (ja) | 1991-05-14 | 1994-08-25 | リプリジェン コーポレーション | Ｈｉｖ感染治療のための異種複合抗体 |
| EP0646178A1 (en) | 1992-06-04 | 1995-04-05 | The Regents Of The University Of California | expression cassette with regularoty regions functional in the mammmlian host |
| US5681746A (en) | 1994-12-30 | 1997-10-28 | Chiron Viagene, Inc. | Retroviral delivery of full length factor VIII |
| US6458939B1 (en) | 1996-03-15 | 2002-10-01 | Millennium Pharmaceuticals, Inc. | Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation |
| US5932418A (en) * | 1996-04-08 | 1999-08-03 | Naiad Systems, Inc. | Fish embryo screening test for genotoxic agents using three different developmental life stages |
| DE69925362T2 (de) * | 1998-02-23 | 2006-01-19 | Phylonix Pharmaceuticals Inc., Cambridge | Screeningverfahren für die aktivität von agenzien unter verwendung von teleosten |
| US6514221B2 (en) | 2000-07-27 | 2003-02-04 | Brigham And Women's Hospital, Inc. | Blood-brain barrier opening |
| AU2001286930A1 (en) | 2000-08-30 | 2002-03-13 | The Board Of Trustees Of The Leland Stanford Junior University | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| US7034036B2 (en) | 2000-10-30 | 2006-04-25 | Pain Therapeutics, Inc. | Inhibitors of ABC drug transporters at the blood-brain barrier |
| US20030083299A1 (en) | 2000-11-04 | 2003-05-01 | Ferguson Ian A. | Non-invasive delivery of polypeptides through the blood-brain barrier |
| DE10121982B4 (de) | 2001-05-05 | 2008-01-24 | Lts Lohmann Therapie-Systeme Ag | Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung |
| US20030129186A1 (en) | 2001-07-25 | 2003-07-10 | Biomarin Pharmaceutical Inc. | Compositions and methods for modulating blood-brain barrier transport |
| US20030162695A1 (en) | 2002-02-27 | 2003-08-28 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| CA2791165C (en) | 2002-12-03 | 2015-02-24 | Blanchette Rockefeller Neurosciences Institute | A conjugate comprising cholesterol linked to tetracycline |
| JP2007505142A (ja) | 2003-09-10 | 2007-03-08 | セダーズ−シナイ メディカル センター | 血液脳関門を通過する薬剤のカリウムチャネル媒介性送達 |
-
2007
- 2007-05-03 US US12/299,449 patent/US20100150928A1/en not_active Abandoned
- 2007-05-03 EP EP07797334A patent/EP2016097A2/en not_active Withdrawn
- 2007-05-03 BR BRPI0710407-3A patent/BRPI0710407A2/pt not_active IP Right Cessation
- 2007-05-03 CN CNA2007800240268A patent/CN101479295A/zh active Pending
- 2007-05-03 AU AU2007247969A patent/AU2007247969A1/en not_active Abandoned
- 2007-05-03 JP JP2009510083A patent/JP2009536526A/ja active Pending
- 2007-05-03 NZ NZ572178A patent/NZ572178A/en not_active IP Right Cessation
- 2007-05-03 WO PCT/US2007/068180 patent/WO2007131133A2/en not_active Ceased
- 2007-05-03 CA CA002651199A patent/CA2651199A1/en not_active Abandoned
- 2007-05-03 MX MX2008013934A patent/MX2008013934A/es not_active Application Discontinuation
-
2008
- 2008-10-22 IL IL194786A patent/IL194786A0/en unknown
-
2012
- 2012-04-25 US US13/455,909 patent/US20120266262A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pietzsch et al. | Human S100A12: a novel key player in inflammation? | |
| JP2009536526A5 (enExample) | ||
| US11098364B2 (en) | Inhibiting the onset of gout | |
| US20120213768A1 (en) | Diagnostic and Therapeutic Uses for B Cell Maturation Antigen | |
| KR20200103018A (ko) | Gpcr 헤테로머 억제제 및 이의 용도 | |
| JP2010525301A (ja) | 子宮内膜癌および前癌の診断、分類および治療の方法 | |
| JP2010063458A5 (enExample) | ||
| Pineda-Alvarez et al. | Missense substitutions in the GAS1 protein present in holoprosencephaly patients reduce the affinity for its ligand, SHH | |
| Batoon et al. | Induction of osteoblast apoptosis stimulates macrophage efferocytosis and paradoxical bone formation | |
| JP7271446B2 (ja) | Ｈｌａ－ｇ転写物およびアイソフォームおよびそれらの使用 | |
| Döring et al. | Identification of a non-canonical chemokine-receptor pathway suppressing regulatory T cells to drive atherosclerosis | |
| JP2023532278A (ja) | 抗原特異的ｔ細胞受容体及びキメラ抗原受容体、並びにがん免疫療法のための免疫シグナル伝達モジュレーションにおける使用方法 | |
| JP2003284574A (ja) | 核酸分子、ポリペプチド、ならびにアルツハイマー病の診断および処置を含むそれらの使用 | |
| US20110014183A1 (en) | Mcam modulation and uses thereof | |
| JP2009515183A (ja) | 新たなタンパク質アイソフォーム及びその使用 | |
| KR20230165212A (ko) | 적혈구 장애의 치료 방법 | |
| JP2009506301A (ja) | Ｐｉｆファミリーの新たなタンパク質アイソフォーム及びその使用 | |
| US8492106B2 (en) | Identification methods for ergothioneine transporter modulators and therapeutic uses thereof | |
| WO2014020070A1 (en) | Tif1-gamma for treating and diagnosing inflammatory diseases | |
| JP2015502166A (ja) | 炎症性疾患の予防及び／又は治療において有用な化合物を同定するスクリーニング法 | |
| AU2017309824B2 (en) | Immune status biomarkers and uses therefor | |
| TWI333978B (en) | Granulysin and uses thereof | |
| JP5378202B2 (ja) | 脳・神経に特異的あるいは神経分化に特異的なバイオマーカー | |
| JP2008509659A5 (enExample) | ||
| JP2016516720A (ja) | Ｔｃｆ７ｌ２変異体並びに診断および薬物スクリーニングアッセイにおけるその使用方法 |